SMARCB1 and nasal cavity and paranasal sinus carcinoma: SMARCA4-deficient sinonasal carcinoma behaves more aggressively compared to the SMARCB1-deficient tumors; two thirds of patients with follow-up died of their disease within one year [32, 33].